Professional Essentials

  • US Professional News
  • FULLTEXT

A shortage of specialists?

  • US Professional News
  • FULLTEXT

Physicians can help sexually traumatized patients

  • US Professional News
  • FULLTEXT

Quality reporting efforts may be counterproductive

  • Patients Will Be Asking

Patients Will Be Asking: Is "man flu" real?

  • US Professional News
  • FULLTEXT

Aussie physician writes name on his surgical cap, starts a global movement

  • US Professional News
  • FULLTEXT

5 ways to optimize revenue

View more

New in Obstetrics/Gynecology

  • The ASCO Post
  • 1 comment

SABCS 2017: 2 Years of Extended Anastrozole Therapy Proved as Effective as 5 Years in Hormone Receptor–Positive Breast Cancer

Postmenopausal women with hormone receptor–positive breast cancer who took the aromatase inhibitor anastrozole for 2 years after an initial 5 years of adjuvant endocrine therapy received an equal benefit to those who took the drug for 5 additional years. The trial results suggest that a shorter duration of treatment may provide sufficient benefits while protecting women from harmful side effects, according to data from the ABCSG-16 trial presented by Gnant et al.

  • The ASCO Post
  • 1 comment

SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer

Among patients with hormone receptor–positive HER2-negative stage II–III breast cancer without clinical evidence of recurrence, those who had circulating tumor cells detected in blood 5 years after diagnosis had an increased risk for late recurrence of breast cancer, according to data presented by Sparano et al.

  • The ASCO Post
  • 1 comment

SABCS 2017: SOLD Trial Data Support Current Standard 12-Month Adjuvant Trastuzumab for HER2-Positive Breast Cancer

Disease-free survival after 9 weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to disease-free survival after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment, according to data from the phase III Synergism or Long Duration (SOLD) clinical trial, presented by Joensuu et al.

  • The ASCO Post
  • 1 comment

SABCS 2017: Phase III EMBRACA Trial Meets Primary Endpoint

Patients with advanced HER2-negative breast cancer with germline <em>BRCA</em> mutations had significantly prolonged progression-free survival when treated with the poly(ADP-ribose) polymerase inhibitor talazoparib, compared with those who received chemotherapy of physician’s choice, according to data from the phase III EMBRACA trial presented by Litton et al.

  • The ASCO Post
  • 1 comment

SABCS 2017: Older Women With Hormone Receptor–Positive Breast Cancer May Receive Similar Benefit From CDK4/6 Inhibitors as Younger Women

Older women with hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase 4/6 inhibitors achieved progression-free survival at a rate similar to that of younger women, according to data presented by Singh et al.

  • Clinical Essentials from Am J Obstet Gynecol
  • no comment

Risk for fetal death with abnormal Dopplers prior to 34 weeks quantified

Data can be used to aid in counseling patients and timely delivery.

  • The ASCO Post
  • 1 comment

SABCS 2017: Acupuncture May Reduce Joint Pain Caused by Aromatase Inhibitor Treatment

Acupuncture significantly reduced joint pain for postmenopausal women with early-stage breast cancer receiving treatment with an aromatase inhibitor compared with both sham acupuncture and no treatment, according to data from the randomized, phase III SWOG S1200 trial presented by Hershman et al.

  • The ASCO Post
  • 1 comment

SABCS 2017: Combination of Pembrolizumab and Trastuzumab Shows Early Promise for Patients With Trastuzumab-Resistant Breast Cancer

A combination of pembrolizumab and trastuzumab tested in patients with trastuzumab-resistant advanced HER2-positive breast cancer was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for pembrolizumab, according to data presented from the phase Ib/II PANACEA trial by Loi et al.

  • The ASCO Post
  • 1 comment

SABCS 2017: MONALEESA-7: Ribociclib Improved Progression-Free Survival for Pre- and Perimenopausal Women With HR-Positive Advanced Breast Cancer

Adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival for pre- and perimenopausal women with advanced hormone receptor (HR)-positive, HER2-negative breast cancer, according to data from the MONALEESA-7 trial presented by Tripathy et al.

Primary Care Oncology Vitals for December 2017
  • Vitals
  • 1 comment

Primary Care Oncology Vitals for December 2017

Enrollment expansion for 4 cancer types in TAPUR study | Breast cancer can re-emerge 20 years later | Intermittent letrozole in breast cancer | Implications of negative screening results history.

  • Clinical Essentials from Obstet Gynecol
  • no comment

ACOG updates practice bulletin on VBACs

Most women with 1 prior cesarean delivery should be counseled about, offered a trial of labor.

  • Clinical Essentials from Am J Obstet Gynecol
  • 1 comment

Calculator to estimate success of IOL with unfavorable cervix created

Calculators are for estimates to be used in counseling, but should not be used in isolation.

  • Clinical Essentials from JAMA Oncology
  • no comment
  • FULLTEXT

Ovarian cancer: multimodal screening may be cost-effective in the US

Markov model was based on data from the UKCOCS trial.

  • The ASCO Post
  • 1 comment

SABCS 2017: Adjuvant Trastuzumab Did Not Improve Outcomes for Patients With HER2-Low Breast Cancer

Adding trastuzumab to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, according to data from the randomized, phase III NSABP B-47 clinical trial presented by Fehrenbacher et al.